MiniMed Group (NASDAQ:MMED) Given New $20.00 Price Target at Bank of America

MiniMed Group (NASDAQ:MMED – Get Free Report) had its target price reduced by research analysts at Bank of America from $27.00 to $20.00 in a research report issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. Bank of America‘s price objective would suggest a potential upside of 82.07% from the stock’s current price.

Several other research firms also recently weighed in on MMED. Evercore began coverage on shares of MiniMed Group in a report on Tuesday, March 31st. They issued an “outperform” rating and a $20.00 target price for the company. Piper Sandler assumed coverage on shares of MiniMed Group in a report on Tuesday, March 31st. They issued a “neutral” rating and a $16.00 target price for the company. Benchmark assumed coverage on MiniMed Group in a research report on Tuesday, May 12th. They issued a “buy” rating and a $20.00 target price for the company. Deutsche Bank Aktiengesellschaft assumed coverage on MiniMed Group in a research report on Tuesday, March 31st. They issued a “buy” rating and a $20.00 target price for the company. Finally, Zacks Research raised MiniMed Group to a “hold” rating in a research report on Thursday, April 9th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, MiniMed Group presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.67.

Get MiniMed Group alerts:

Read Our Latest Analysis on MMED

MiniMed Group Trading Up 1.7%

Shares of NASDAQ:MMED traded up $0.19 during midday trading on Monday, reaching $10.99. 357,040 shares of the company’s stock were exchanged, compared to its average volume of 889,689. The stock has a 50 day moving average price of $14.21. MiniMed Group has a fifty-two week low of $10.65 and a fifty-two week high of $20.48.

About MiniMed Group

(Get Free Report)

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.

Featured Articles

• Five stocks we like better than MiniMed Group
• Why Applied Optoelectronics Stock May Be Near a Turning Point
• From High-Yield to High-Growth: 3 Stocks Boosting Dividends
• Is Everspin Technologies the Next AI Edge Breakout?
• 5 Robotics Stocks to Watch as Physical AI Builds Momentum

Receive News & Ratings for MiniMed Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiniMed Group and related companies with MarketBeat.com's FREE daily email newsletter.